Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., ...

Merck Animal Health announced today the FDA approved atinvicitinib tablets (NUMELVI; Merck Animal Health), making it the first and only second-generation Janus kinase (JAK) inhibitor indicated for ...

Figure 1: Ruxolitinib exerts its anti-myeloma effects through several mechanisms. “[...] the results of the studies presented in this review will hopefully provide the impetus for conducting ...

By blocking the JAK and ROCK pathways, rovadicitinib offers a differentiated mechanism of action to best-selling, single-target GVHD drugs like Jakavi and Imbruvica.

JAK inhibitors, a new class of tsDMARDs, have shown superior efficacy in RCTs for RA compared to other biologics. Real-world studies highlight JAK inhibitors' benefits in clinical disease activity, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. MIAMI BEACH, Fla. — Janus kinase inhibitors are an ...

A new research perspective titled "Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma" has been published in Oncotarget. In this new paper, researchers ...

JAK inhibitors like baricitinib, ritlecitinib, and brepocitinib show promise in treating alopecia areata, with baricitinib approved by FDA and EMA. Baricitinib significantly reduced SALT scores at 24 ...

Previous, smaller studies had found that patients tended to gain weight while on the Janus kinase (JAK) inhibitor tofacitinib. This study, funded by tofacitinib's manufacturer, analyzed data from more ...

IMM2510, an anti-PD-L1/VEGF bispecific antibody fusion protein, in patients with R/R STS: A phase Ib expansion study. Gamma secretase inhibitors and desmoid fibromatosis: Lessons from a real world, ...